默沙东、艾伯维等超4家跨国药企公布2025年上半年业绩,多家发展稳健

制药网
04 Aug

【制药网 行业动态】2025年上半年,全球医药头部们的业绩答卷呈现出鲜明的分化态势。截至目前,已经披露“成绩单”的超4家跨国药企中,艾伯维、阿斯利康、强生等企业凭借产品迭代与市场深耕实现稳健增长,而默沙东则因核心产品增速放缓与区域市场受挫面临转型阵痛。新旧交替:艾伯维的“后Humira时代”逆袭艾伯维上半年以8%的营收增速(287.66亿美元)交出亮眼成绩单,其核心驱动力来自免疫学双雄...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10